New therapies cut breast cancer treatment time by 70-90%, experts say – The New Indian Express

0

Express press service

NEW DELHI: Advanced and new therapies for breast cancer are now saving doctors and patients up to 70-90% in treatment time. With Phesgo – a newer breast cancer treatment launched recently in India – oncologists in leading hospitals are seeing the release of capacity to treat more patients in cancer centers given the overall burden of cancer.

The cost of treating breast cancer, which is the leading cause of cancer among women in India, has also fallen by up to 20%, experts have said.

As October is considered Breast Cancer Awareness Month, eminent experts have pointed out that India has come a long way in treating breast cancer, if detected early, thanks to the cutting-edge technology and drugs, with increasing survival rates.

“Breast cancer has become the number one cancer among women in India. It even surpassed cervical cancer. More than 1.8 lakh cases of breast cancer are reported every year in India,” said Dr. Shyam Aggarwal, Senior Consultant in Surgical Oncology at Sir Ganga Ram Hospital.

Since breast cancer is less known, it is detected at an advanced stage, which puts India behind the western world, where early detection of breast cancer is widespread.

“Over the years, we have made tremendous progress in the management of breast cancer. Previously, we talked about radical surgeries like the removal of the entire breast. We don’t talk about it in many patients because of early detection.

There is a paradigm shift and doctors are now keeping lots of breasts, an essential organ for a woman. He added that new therapies have become essential in the management not only in advanced stages, but even in the early stages.

Dr Pragya Shukla, Head of Department and Assistant Professor (Clinical Oncology) at the Delhi State Cancer Institute, said more than 1,000 patients check their OPD daily.

Talking about how new therapies have helped them treat cancer patients, she said: “We provide Phesgo for free at our center where the poorest of the poor come for treatment. These expensive drugs were not included in government structures before, but we provide them. This expensive molecule is necessary because every life matters.

She said administering medication frees up time for everyone – patients, carers, doctors and paramedics. “We are happy that such a drug has arrived, which has reduced the time, and it helps us to provide treatment to more patients.”

Swiss multinational pharmaceutical company Roche launched the drug earlier this year. It is a combination of two monoclonal antibodies administered in a single injection, thus significantly reducing treatment time by up to 90%. The drug combines Perjeta and Herceptin with hyaluronidase and reduces the cost of treatment by 20%. It costs Rs. 2.8 lakh per dose

“Cancer is curable; it is not a death sentence,” she added.

Describing cancer as a silent epidemic, Dr. Sajjan Rajpurohit, Director of Medical Oncology, BLK Max Hospital, said Phesgo is safely delivered at the bedside in just 2-4 hours, which previously would take two to three days and the patient had to be admitted.

Dr. Meenu Walia, Senior Director of Department of Medical Oncology at Max Super Specialty Hospital, said better diagnostic modalities, technologies and new therapies have improved the treatment of breast cancer patients in India.

“There was a time when all breast cancer patients were treated the same. Now there are many new therapies. Gone are the days when only chemotherapy or hormone therapies were available. Today we have cutting-edge drugs and improved technologies that deliver targeted drugs that have made a big difference.

“We’ve seen that many late-stage cancer patients live for years on these therapies,” she said.

“We are detecting more cases of breast cancer now because lifestyles are changing. We eat junk food, we don’t walk or exercise, and our diet is not healthy, and it is also hereditary. Breast self-examination is the best way to detect breast cancer.” added Dr. Walia.

Lifestyle issues

Phesgo is a new fixed-dose subcutaneous (SC) formulation that combines Perjeta (pertuzumab) and Herceptin (trastuzumab).

It is administered under the skin as a single injection just under the skin of the thigh

This is the world’s first fixed-dose combination of two monoclonal antibodies in oncology

Over 400 breast cancer patients across the country are using Phesgo now

It provides a faster, more convenient and less invasive way to receive breast cancer treatment

According to the World Health Organization, there were 2.3 million women diagnosed with breast cancer and 6.85 lakh deaths globally in 20209.

While 90-95% of breast cancers are due to lifestyle issues, 5-10% are due to inherited diseases.

Breast cancer has ranked the number one cancer among Indian women, with a mortality rate of 12.7/per 100,000 women.

India is seeing more triple-negative breast cancer, which tends to grow and spread faster, has fewer treatment options and tends to have a poorer prognosis

About 20% of all breast cancers are HER2+ve. It is considered more aggressive

NEW DELHI: Advanced and new therapies for breast cancer are now saving doctors and patients up to 70-90% in treatment time. With Phesgo – a newer breast cancer treatment launched recently in India – oncologists in leading hospitals are seeing the release of capacity to treat more patients in cancer centers given the overall burden of cancer. The cost of treating breast cancer, which is the leading cause of cancer among women in India, has also fallen by up to 20%, experts have said. As October is considered Breast Cancer Awareness Month, eminent experts have pointed out that India has come a long way in treating breast cancer, if detected early, thanks to the cutting-edge technology and drugs, with increasing survival rates. “Breast cancer has become the number one cancer among women in India. It even surpassed cervical cancer. More than 1.8 lakh cases of breast cancer are reported every year in India,” said Dr. Shyam Aggarwal, Senior Consultant in Surgical Oncology at Sir Ganga Ram Hospital. Since breast cancer is less known, it is detected at an advanced stage, which puts India behind the western world, where early detection of breast cancer is widespread. “Over the years, we have made tremendous progress in the management of breast cancer. Previously, we talked about radical surgeries like the removal of the entire breast. We don’t talk about it in many patients because of early detection. There is a paradigm shift and doctors are now keeping lots of breasts, an essential organ for a woman. He added that new therapies have become essential in the management not only in advanced stages, but even in the early stages. Dr Pragya Shukla, Head of Department and Assistant Professor (Clinical Oncology) at the Delhi State Cancer Institute, said more than 1,000 patients check their OPD daily. Talking about how new therapies have helped them treat cancer patients, she said: “We provide Phesgo for free at our center where the poorest of the poor come for treatment. These expensive drugs were not included in government structures before, but we provide them. This expensive molecule is necessary because every life matters. She said administering medication frees up time for everyone – patients, carers, doctors and paramedics. “We are happy that such a drug has arrived, which has reduced the time, and it helps us to provide treatment to more patients.” Swiss multinational pharmaceutical company Roche launched the drug earlier this year. It is a combination of two monoclonal antibodies administered in a single injection, thus significantly reducing treatment time by up to 90%. The drug combines Perjeta and Herceptin with hyaluronidase and reduces the cost of treatment by 20%. It costs Rs. 2.8 lakh per dose “Cancer is curable; it is not a death sentence,” she added. Describing cancer as a silent epidemic, Dr. Sajjan Rajpurohit, Director of Medical Oncology, BLK Max Hospital, said Phesgo is safely delivered at the bedside in just 2-4 hours, which previously would take two to three days and the patient had to be admitted. Dr. Meenu Walia, Senior Director of Department of Medical Oncology at Max Super Specialty Hospital, said better diagnostic modalities, technologies and new therapies have improved the treatment of breast cancer patients in India. “There was a time when all breast cancer patients were treated the same. Now there are many new therapies. Gone are the days when only chemotherapy or hormone therapies were available. Today we have cutting-edge drugs and improved technologies that deliver targeted drugs that have made a big difference. “We’ve seen that many late-stage cancer patients live for years on these therapies,” she said. “We are detecting more cases of breast cancer now because lifestyles are changing. We eat junk food, we don’t walk or exercise, and our diet is not healthy, and it is also hereditary. Breast self-examination is the best way to detect breast cancer.” added Dr. Walia. Lifestyle issues Phesgo is a new fixed-dose subcutaneous (SC) formulation that combines Perjeta (pertuzumab) and Herceptin (trastuzumab). It is administered under the skin in a single injection just under the skin of the thigh It is the world’s first fixed-dose combination of two monoclonal antibodies in oncology More than 400 breast cancer patients worldwide countries are now using Phesgo It provides a faster and more effective solution a convenient and less invasive way to receive treatment for breast cancer According to the World Health Organization, 2.3 million women have been diagnosed with breast cancer breast cancer and 6.85 lakh died globally in 20209. While 90-95% of breast cancers are due to lifestyle issues, 5-10 percent is due to hereditary breast cancer ranked the number one cancer among Indian women, with a mortality rate of 12.7/per 100,000 women. India is seeing more triple negative breast cancers, which tend to grow and spread faster, have fewer treatment options and tend to have a poorer prognosis. About 20% of all breast cancers are HER2+ve. It is considered more aggressive

Share.

Comments are closed.